| 1956v3 | |
| Variant ID | 1956v3 |
| Name | First generation TKI-resistant EGFR mutation |
| Gene | EGFR epidermal growth factor receptor [KO:K04361] |
| Organism | hsa_var Human gene variants (Homo sapiens) |
| Variation | mutation T790M ClinVar: 16613 dbSNP: rs121434569 VARIATION exon 19 deletion ClinVar: 177620 dbSNP: rs727504233 VARIATION mutation L858R ClinVar: 16609 376282 376280 dbSNP: rs121434568 rs1057519848 rs1057519847 |
| Map | nt06210 ERK signaling nt06214 PI3K signaling nt06220 Calcium signaling nt06266 Non-small cell lung cancer |
| Network | N00014 Mutation-activated EGFR to RAS-ERK signaling pathway N00024 Mutation-activated EGFR to PLCG-ERK signaling pathway N00036 Mutation-activated EGFR to PI3K signaling pathway N10006 Third-generation tyrosine kinase inhibitor to EGFR mutation DISEASE H00014 Non-small cell lung cancer H00042 Glioma DRUG_TARGET Aumolertinib (DG03209): D12258 D12259 Lazertinib (DG03205): D11980 D12245 Osimertinib: D10766 |
| Reference | PMID:28149837 AUTHORS Sullivan I, Planchard D TITLE Next-Generation EGFR Tyrosine Kinase Inhibitors for Treating EGFR-Mutant Lung Cancer beyond First Line. JOURNAL Front Med (Lausanne) 3:76 (2016) DOI:10.3389/fmed.2016.00076 |